Over the past year, AbbVie (ABBV) has settled patent lawsuits with a growing number of drug makers that will delay biosimilar versions of its Humira rheumatoid arthritis medicine from becoming available in the U.S. until 2023. But one company has so far refused to settle and the litigation is yielding purported details that shed light on AbbVie’s use of a so-called patent thicket to defend its franchise product.

Among the allegations is that AbbVie re-patented certain claims and processes for making the drug when, in fact, the approach was already in use, yet the company did not provide this information to the U.S. Patent and Trademark Office, according to court documents filed by Boehringer Ingelheim. In effect, re-patenting processes that were not actually invented became a purported vehicle for crowding out would-be rivals.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy